Association Between SGLT2 Inhibitors and DPP-4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case-Based Analyses
Large Korean health data confirm two common diabetes medications don't increase pancreatitis risk, supporting their safe continued use.
Using Korean national health insurance data on 7,219 acute pancreatitis cases (2018–2020), two complementary epidemiological designs confirmed that neither SGLT2 inhibitors nor DPP-4 inhibitors increase acute pancreatitis risk in T2DM patients. These reassuring safety findings, using robust self-controlled methodology to account for prescription trends, support continued confidence in these drug classes for diabetes management.
What the study was
- Study design
- Nationwide case-case-time-control analysis + nested case-control study using Korean national health insurance database
- Population
- Korean patients with type 2 diabetes mellitus (2018–2020)
- Sample size
- 7219
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Diabetes, Obesity & Metabolism
Why it surfaced
Large nationwide pharmacoepidemiological study (n=7219 AP cases) with dual robust design confirming safety of SGLT2i and DPP-4i re: pancreatitis. Directly relevant to a widely debated clinical concern. Strong design (case-case-time-control + nested case-control).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.